Introduction
Each year in the USA, more than 1 000 000 people receive a serious traumatic brain injury and the number is even higher in rapidly developing countries such as China. 1 This is often associated with acute spinal cord injury (ASCI). Many factors cause poor repair after ASCI, including lack of growthpromoting factors, the poor intrinsic regenerative capacity of neurons in the central nervous system, 2,3 chemorepulsive molecules 4 and glial scar-associated inhibitors such as chondroitin sulphate proteoglycans (CSPGs). 5 It has been reported that, after ASCI, not only is there a change in neuron growth and function, but there are also decreases in serum levels of dihydroepiandrosterone, insulin and parathyroid hormone. 6 Insulin is a hormone of 51 amino acid residues and has profound effects on metabolism, stimulating most body cells to take up glucose from the blood and storing it as glycogen in the liver and muscle. 7 When insulin is absent or when its concentration is low, glucose is not properly taken up by most body cells and the cells begin to use fat as an energy source. 8 Insulin is now widely used to treat patients with type 2 diabetes mellitus. 9 Insulin levels decrease after ASCI 6 and insulin has, therefore, recently been used in various ways to treat spinal cord injury. Insulin has been shown to rescue embryonic stem cell-derived neural progenitor cells from apoptosis by differential regulation of the protein kinase B (Akt) and extracellular signal-related kinase (ERK) pathways. 10 Insulin also plays roles in the regulation of
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neuronal cell death and neurological deficits, 11 prompting study of the effect of insulin on ASCI. Chondroitinase ABC (ChABC), a soluble enzyme, forms the carbohydrate branch of CSPG molecules. 12 CSPGs are extracellular matrix molecules that are up-regulated around sites of injury to the central nervous system 12 and inhibit neurite outgrowth in vitro and in vivo. 13 21 GAP-43 is specific to nervous tissue and is highly expressed in neurons during development and nerve regeneration, as well as being associated with neurite outgrowth, long-term potentiation, signal transduction and neurotransmitter release. 21 GAP-43 is synthesized and transported along the axon during the regeneration and development of axons. 22 GAP-43 is considered to be the same protein as the following: pp46, which is localized in growth cone membranes during embryogenesis; B50, which is present in mature pre-synaptic membranes and involved in the regulation of phosphatidylinositol turnover; and protein F1, which is involved in long-term potentiation in the hippocampus. 23 The expression of GAP-43 was increased in axons after compression trauma in different parts of the rat spinal cord, 22 and GAP-43 was also expressed in different parts of the spinal cord at various times after injury and treatment. 15, 24 Little is known, however, about changes in GAP-43 expression when cells are treated with insulin and ChABC together.
In the present study, an ASCI rat model was established by using an improved version of Allen's method. 25 The present study was designed to investigate the therapeutic effect of combined treatment with insulin and ChABC on the recovery of motor and sensory neuron function, cell growth and apoptosis of neurons.
Materials and methods

ANIMALS AND TREATMENT GROUPS
Adult male and female Sprague-Dawley rats (weighing 180 -250 g) were used in this study. ASCI was induced in Sprague-Dawley rats by extradural compression using a modification of Allen's method. 25 The rats were randomly divided into the following five groups: group A, treated with saline (control group); group B, treated with insulin; group C, treated with ChABC; group D, treated with insulin plus ChABC; and group E, treated with methylprednisolone. Each group was further divided into smaller subgroups that were examined 1 day, 3 days, and 1, 2, 4 and 8 weeks after injury.
Animal care was carried out in accordance with the guidelines of Chongqing Medical University Animal Care and Use Committee.
SURGICAL PROCEDURES
Rats were deeply anaesthetized by intraperitoneal injection of chloral hydrate (300 mg/kg). Laminectomy was performed to expose the T8 -T10 dorsal portion of the spinal cord. The T9 dura mater was pierced with a copper cylinder of 3 mm in diameter Insulin with chondroitinase ABC for acute spinal cord injury and the spinal cord was exposed. A moderate or severe contusion injury was made using a weight-drop device according to a modification of Allen's method, 25 in which a 10 g rod, 3 mm in diameter and 100 mm in length, was dropped onto the exposed spinal cord surface, applying a force of 10 5 g. In groups A and B, the overlying muscle and skin were then sutured. In groups C and D the microinjector was left in the dorsal over-hemisection lesion from T9 to T10 with a polyethylene 0402 tube (outside diameter 0.4 mm, inside diameter 0.2 mm).
In group E, a dorsal lesion was made in the tail vein with a 4-gauge in-dwelling needle and flushed with 1 ml sodium heparin. All rats in all study groups were given an intraperitoneal injection of penicillin G at 10 5 U/day, and the wound was sterilized with povidone iodine. The rats were then housed singly in cages at room temperature with free access to drinking water and food.
Spinal cord tissues were collected and fixed at intervals after injury, and the spinal cord injury was identified in the tissue samples by haematoxylin/eosin and Nissl staining.
DRUG TREATMENT
The different treatments were started 30 min after spinal cord injury. Rats in the control group (group A) received an intraperitoneal injection of 1.0 ml saline every day for 1 week. Rats in group B received an intraperitoneal injection of 1 IU/kg insulin plus 1 g/kg glucose (as a 50% solution) three times a day for 1 week (i.e. the total daily dose was 3 IU/kg insulin plus 3 g/kg glucose). In group C, the tail was connected to a microinjector tube after spinal cord injury. The first treatment was an injection of 6 µl ChABC (C2905-2UN, 1 U/ml; Sigma-Aldrich, St Louis, MO, USA) and 6 µl of saline was given on each of the subsequent 6 days. Rats in group D were treated with insulin plus ChABC, each being administered as described for groups B and C. Rats in group E were injected with methylprednisolone through the tail vein, the first time at 30 mg/kg and then at 5.4 mg/kg at intervals of 45 min for 23 h.
LOCOMOTOR BEHAVIOUR
Locomotor behaviour was monitored and scored using the Basso, Beattie and Bresnahan (BBB) open field test. 26 The range of BBB scores for the rats was 0 -25, a higher score indicating better locomotor performance. Locomotor behaviour was tested once every 2 -4 days during the first 2 weeks after injury, then once a week until the end of the experiments (2 months after injury). On each occasion the test was blinded and repeated three times.
NEUROELECTROPHYSIOLOGICAL STUDY
A neuroelectrophysiological study was performed once every 2 -4 days during the first 2 weeks after injury and subsequently once a week until the end of the experiments (2 months after injury). The spinal cord evoked potential (SCEP) and motor evoked potential (MEP) were measured as described previously. 27 Briefly, the rats were anaesthetized with urethane (1.5 g/kg), the dura mater was exposed at T8 -T10, and the latency and amplitude of SCEP and MEP were then recorded. SCEP was elicited by electrical stimulation of the gastrocnemius belly at a site 2 mm from the spinal cord lesion (BL-410 amplifier pulses set at 3.3 kHz, 0.01 s, 20 ms/div, 500 G). The MEP was recorded in the space between the T8 and T10 spinal epidural at 20.00 ms/div, 1000 G, 0.01 s, 3.3 kHz. For each experiment, the optimal stimulation site was mapped, signals from T8 were recognized and imaged as the proximal MEP and those from T10 as the distal MEP, Insulin with chondroitinase ABC for acute spinal cord injury and the signals were analysed with BL-New Century software (Taimeng Science and Technology Co. Ltd, Chengdu, China).
APOPTOSIS
Cell apoptosis was detected dynamically by the use of terminal deoxynucleotidyl transferase (TdT)-mediated deoxyuridine triphosphate (dUTP) nick-end labelling (TUNEL) staining in spinal cord tissues. TUNEL was performed using a APO-BrdU™ (TUNEL) Assay Kit (United BioSource, Wayne, PA, USA) according to the manufacturer's instructions and as previously reported. 28 Slides were observed and TUNEL staining was measured by fluorescence microscopy.
IMMUNOCHEMICAL ASSAY FOR GAP-43
At the appropriate time point following spinal injury and treatment, all animals were transcardially perfused with 4% paraformaldehyde. The spinal cord with the spinal column (T8 -T10) was then removed and post-fixed with 4% paraformaldehyde. Spinal cord tissue was separated 12 h later, fixed overnight and embedded in 10% gelatin for immunohistochemical processing. Anti-GAP-43 primary antibody (1:1000 dilution; Sigma-Aldrich) and avidinconjugated or biotin-conjugated secondary antibodies were applied. The percentage of GAP-43-positive cells was determined in four sections per animal. All images were photographed using Simple PCI 5.1 Imaging Systems (Compix, Lake Oswego, OR, USA), and the number of positive cells per highpower field was counted at 100× magnification.
NEURON-TRACING ASSAY
For detection of axon growth and nerve fibres, neuron-tracing assay was performed as previously described. 29 Briefly, rats were anaesthetized with 300 mg/kg chloral hydrate 7 weeks after ASCI, and the spinal column was then exposed at T10 and pressure injected with 1 µl biotinylated dextran amine (BDA) (BDA-
STATISTICAL ANALYSIS
Morphometric data were analysed using either a t-test or a one-way analysis of variance with Tukey's HSD (Honestly Significant Difference) test for post-injury comparisons. Locomotor behaviour data were analysed using the non-parametric Mann-Whitney test. A P-value of < 0.05 was considered to be statistically significant. All statistical analyses were performed using SYSTAT ® version 11 (SYSTAT Software, Chicago, IL, USA) for Windows ® .
Results
CONSTRUCTION OF THE ASCI RAT MODEL
A total of 180 adult male and female Sprague-Dawley rats (weighing 180 -250 g) were used in this study. All rats showed a typical paraplegia syndrome after spinal cord surgery, with paralysis, hypomyotonia, extended abdominal muscle palsy, enteroparalysis, haematuria and conjunctival haemorrhage. The rats were able to move 12 h later but dragged both hind legs with the acrotarsium on the Insulin with chondroitinase ABC for acute spinal cord injury ground. Haematoxylin/eosin and Nissl staining of slices of spinal cord tissues showed extensive haemorrhage, exosmotic red cells, condensed neuronal nuclei, enhanced staining with gradual pycnosis, necrosis and diffuse inflammatory infiltration in the spinal grey matter (data not shown), indicating the successful construction of an ASCI model.
INSULIN WITH CHABC RESCUES SPINAL CORD LOCOMOTOR AND SENSOR FUNCTION
The BBB open field test was used to evaluate locomotor behaviour. The BBB scores of rats treated with insulin, insulin plus ChABC or methylprednisolone were significantly higher than those of rats treated with ChABC alone and those in the control group (P < 0.05), from 2 weeks after injury (Fig. 1A) . The hindleg activity of rats treated with insulin, insulin plus ChABC or with methylprednisolone had more power than rats in the control or ChABC-treated groups. At 4 weeks after spinal cord injury, the rats in the groups treated with insulin, insulin plus ChABC or with methylprednisolone could walk normally, but the control rats and rats treated with ChABC alone could not. At 8 weeks after injury, the mean BBB scores of rats in the groups treated with insulin, insulin plus ChABC or methylprednisolone were > 18, but were < 15 in the other two groups (Fig.  1B) . Locomotor ability in the groups treated with insulin, insulin plus ChABC or methylprednisolone was much stronger than that of the control or ChABC-only groups.
The SCEP and MEP latencies and amplitudes were measured to evaluate further changes in sensory function. From 0 to 2 weeks after injury, SCEP in rats treated with insulin, insulin plus ChABC or methylprednisolone gradually recovered in latency and amplitude, whereas in the control rats and rats treated with ChABC alone there were no obvious changes. At 4 and 8 weeks after injury, SCEP latency and amplitude were similar in all treatment groups ( Fig. 2A, 2B ). The MEP latency and amplitude at the proximal position could not be detected 1 week after injury. From 1 to 2 weeks after injury, MEP latency and amplitude at the proximal position gradually recovered in the rats treated with insulin or insulin plus ChABC or methylprednisolone, whereas values in control rats and rats treated with ChABC alone could still not be measured. From 1 to 2 weeks after injury, recovery was obvious in the rats treated with insulin or insulin plus ChABC or methylprednisolone, and MEP latency and amplitude at both the proximal Fig. 2C, 2D ) and distal ends (data not shown) of the injury of the spinal cord could be detected. The response at the distal end was more evident, exhibiting shorter latency and higher amplitude in rats treated with insulin, insulin plus ChABC, or methylprednisolone than in control rats and rats treated with ChABC alone.
INSULIN PLUS CHABC PROMOTES NEURON GROWTH
Apoptotic cells were observed in rat spinal cord tissues 1 day after injury in the grey and white matter. The number of apoptotic cells increased to a maximum in all groups 1 week after injury and then decreased, although there were significantly fewer apoptotic cells in spinal cord tissue from rats treated with insulin, insulin plus ChABC or methylprednisolone than in tissue from control rats or rats treated with ChABC alone (P < 0.05; Fig. 3A, 3B ). There were fewer apoptotic cells in all groups 4 weeks after injury than at earlier time points and apoptotic cells were not detectable 8 weeks after injury. To detect axon growth and nerve fibres, neuron-tracing assay found that regenerated neural axons passed through the vesicle cavity in rats treated with insulin, insulin plus ChABC or methylprednisolone, but not in the control group or in the group treated with ChABC alone. More nerve fibres and longer axons were found in rats treated with insulin, insulin plus ChABC or methylprednisolone than in rats of the other two groups (Fig. 3C) . These results suggest that treatment with insulin or insulin plus ChABC may prevent cell death.
INSULIN WITH CHABC INCREASES GAP-43 EXPRESSION
Because GAP-43 is related to neuron regrowth in the spinal cord, 30 the expression of GAP-43 was investigated by immunohistochemistry. Cells positive for GAP-43 appeared 1 day after injury; more were seen in the grey matter than in the white matter. GAP-43 expression reached a peak 7 days after injury and then decreased (data not shown). The expression of GAP-43 in spinal cord tissue was measured 7 days after injury. More GAP-43-positive cells and darker staining was seen in rats treated with insulin, insulin plus ChABC or methylprednisolone than in control rats and rats treated with ChABC alone (Fig. 4A) . The expression of GAP-43 in rats treated with insulin, insulin plus ChABC or methylprednisolone was significantly greater than in the other two groups 7 days after injury (P < 0.05; Fig. 4B ), indicating better neuron regeneration with these treatments.
Discussion
Serious traumatic brain injury is a worldwide social and medical problem, especially in rapidly developing countries. There are many reasons for repairing neurons and restoring their functions, 2 -4 and researchers are seeking better ways to do this following spinal cord injury. Insulin, the traditional drug used to treat diabetes, was used in the present study as a potential new treatment for ASCI, due to its decreased serum levels 6 and its anti-apoptotic role in the control of cell death and neurological deficit in ASCI models. 11 The results clearly showed that treatment with insulin may promote recovery of the locomotor and neuroelectrophysiological functions of the spinal cord, hinder neuron apoptosis and promote neuron growth. These recovery functions appeared soon after insulin treatment was begun in ASCI rats, becoming evident within 2 weeks after injury and persisting until the end of the observation period 8 weeks after injury. This observation supports the curative effect of insulin in ASCI models and its wide Insulin with chondroitinase ABC for acute spinal cord injury use in the future for treating neurological trauma. Moreover, in this ASCI model, the effectiveness of the combination of insulin with ChABC in promoting neuron recovery was better than that of insulin alone.
ChABC, a soluble enzyme that degrades chondroitin sulphate-glycosaminoglycan, has been reported to upregulate a regeneration-associated protein in injured neurons and to promote the regeneration of ascending sensory projections and the functional recovery of locomotor and exploratory behaviours. 15 -17 Although the recovery effect of ChABC alone was not In summary, the present study shows that insulin, the traditional drug for diabetes, may prevent neuronal cell death and promote the recovery of locomotor and sensory function after ASCI. The combination of insulin and ChABC had a greater beneficial effect than insulin alone in ASCI treatment. These data suggest that a combination of insulin and ChABC could provide a basis for an effective future treatment for ASCI.
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